# EuBiologics Projects 135 Billion Won Sales as Cholera Vaccine Contract Ships > EuBiologics expects 135 billion won in sales and 45 billion won operating profit this year as it begins shipping a 51.6 billion won cholera vaccine contract. - Published: 2026-10-27T05:20:25+00:00 - Section: Earnings & Results - Author: News Desk - URL: https://newsforagent.com/news/2026-10-27/eubiologics-cholera-vaccine-profit-outlook - Source: [Naver](https://n.news.naver.com/mnews/article/421/0009252677) ## Key takeaways - EuBiologics expects 135 billion won in sales and 45 billion won in operating profit this year, according to a Yuho Securities projection. - The company began shipping a 51.6 billion won cholera vaccine supply contract announced in the second quarter. - EuBiologics submitted an IND for Phase 2 trials of its shingles vaccine EuHZV in South Korea. [EuBiologics](https://akta.pro/company-profiles/000n8qg/eubiologics) expects to lift second-half profit by shipping a 51.6 billion won cholera vaccine supply contract, with Yuho Securities projecting 135 billion won in sales and 45 billion won in operating profit for the year. The company announced the plans on Monday, according to [Naver](https://n.news.naver.com/mnews/article/421/0009252677). ## EuBiologics Cholera Vaccine Contract and Full-Year Outlook EuBiologics reported first-half sales of 48.9 billion won and an operating profit of 10.8 billion won. The company attributed the result to timing differences in revenue recognition based on shipment schedules and a high comparison base from the previous year. It expects improved performance in the third and fourth quarters as shipments of the 51.6 billion won cholera vaccine contract begin. Last year, EuBiologics posted record results with sales of 149.2 billion won and an operating profit of 60.7 billion won. Its operating profit margin reached 40.7%, supported by the efficiency of its cholera vaccine, Euvichol-S. EuBiologics is a South Korean biopharmaceutical company that develops, manufactures and supplies WHO-prequalified oral cholera vaccines to UNICEF and global health agencies, with a pipeline spanning conjugate, RSV, shingles and Alzheimer's vaccines. ## EuBiologics Shingles and Alzheimer's Vaccine Pipeline The company's shingles vaccine, EuHZV, recently submitted an investigational new drug application for Phase 2 clinical trials in South Korea. Phase 1 results showed no serious adverse reactions or events, and upcoming trials will compare its immunogenicity to GSK's Shingrix. GSK's Shingrix generated approximately 6.3 trillion won in worldwide sales last year. EuBiologics aims to use its proprietary adjuvant EcML and antigen display technology SNAP to achieve competitive manufacturing costs for domestic and international markets. Its Alzheimer's therapeutic vaccine, PadiVax, recently submitted an IND for Phase 1 clinical trials in South Korea. PadiVax targets both amyloid beta and tau proteins and is designed to stimulate the body's own antibody production. A EuBiologics spokesperson said the company plans to diversify its public vaccine portfolio, including typhoid vaccines, while advancing its shingles and Alzheimer's vaccines through clinical trials. ## EuBiologics Funding and Manufacturing Records According to akta.pro [company records](https://akta.pro/company-data), EuBiologics approved a 111.5 billion won investment in February 2026 to build a third production plant in Chuncheon, Gangwon Province, scheduled for completion through 2028. The same records show 2024 revenue of 149 billion won, up 76.8% year over year, and 2024 operating profit of 60.7 billion won, up 55.4% year over year. ## EuBiologics Typhoid and Adjuvant Milestones EuBiologics' typhoid conjugate vaccine EuTYPH-C received WHO prequalification in August 2026, becoming the first vaccine backed by the RIGHT Foundation to clear the bar, Naver reported in September 2026. The Korea Herald reported in August 2026 that the prequalification enables the company to bid for international public procurement programs. In July 2026, EuBiologics completed registration of its proprietary EcML vaccine adjuvant with the FDA's Drug Master File system, obtaining an official filing number to support future vaccine development and licensing partnerships, The Korea Herald reported. ## What Comes Next for EuBiologics EuBiologics' shingles vaccine EuHZV and Alzheimer's therapeutic vaccine PadiVax have both submitted IND applications for clinical trials in South Korea. The third production plant in Chuncheon is scheduled for completion through 2028. ## Companies in this story - [EuBiologics company profile](https://akta.pro/company-profiles/000n8qg/eubiologics) · website: http://www.eubiologics.com/en/main --- News for Agent · https://newsforagent.com/llms.txt